https://biotechmorning.com/news/roche-obesity-drug-party Biotech Morning en 2026-09-30T14:18:39.354Z Roche Just Crashed the Obesity Drug Party. Did It Bring Enough to Stay? https://biotechmorning.com/news/uniqure-huntington-gene-therapy-durability-loss Biotech Morning en 2026-09-30T14:17:52.619Z The Gene Therapy That Worked for 3 Years, Then Stopped Working https://biotechmorning.com/news/oral-il-17a-inhibitor-psoriasis-ascletis Biotech Morning en 2026-09-30T14:16:59.112Z The Pill That Wants to Replace Your Psoriasis Injection https://biotechmorning.com/news/roche-autonomous-ai-labs Biotech Morning en 2026-09-30T14:16:12.453Z Roche Wants to Fire Its Lab Scientists (and Replace Them With Robots) https://biotechmorning.com/news/peanut-patch-seven-years-fda-door Biotech Morning en 2026-09-30T14:15:29.583Z The Peanut Patch That Took Seven Years to Reach the FDA's Door https://biotechmorning.com/news/phrma-eric-cantor-ceo-former-congressman Biotech Morning en 2026-09-30T14:14:42.872Z Big Pharma's New Weapon Against Washington Is a Former Congressman https://biotechmorning.com/news/amgen-lupus-graveyard-phase-2-win Biotech Morning en 2026-09-30T14:13:58.871Z Amgen Just Survived Biotech's Most Notorious Graveyard https://biotechmorning.com/news/beam-therapeutics-trade-secret-lawsuit-yoltech-serapha Biotech Morning en 2026-09-30T14:13:13.693Z Beam Therapeutics Says a Scientist Walked Out With Its Secret Recipe https://biotechmorning.com/news/obesity-drug-petrelintide-lower-dose-twist Biotech Morning en 2026-09-30T14:12:32.127Z The Obesity Drug That Worked Better at a Lower Dose https://biotechmorning.com/news/lilly-retatrutide-phase-3-obesity-data Biotech Morning en 2026-09-30T14:11:43.321Z Eli Lilly's New Weight-Loss Drug Just Made the Competition Look Small https://biotechmorning.com/news/mrna-vaccine-no-freezer-ai-lipid-nanoparticles Biotech Morning en 2026-09-29T14:18:49.465Z The mRNA Vaccine That Doesn't Need a Freezer https://biotechmorning.com/news/novo-nordisk-2-6-billion-hengrui-preclinical-glp1 Biotech Morning en 2026-09-29T14:18:05.315Z Novo Just Paid $2.6 Billion for a Drug Nobody's Tested in Humans https://biotechmorning.com/news/astrazeneca-2-billion-summit-therapeutics-ivonescimab Biotech Morning en 2026-09-29T14:17:18.467Z AstraZeneca Just Wrote a $2 Billion Check for a Drug It Doesn't Own https://biotechmorning.com/news/novartis-avidity-12-billion-bet Biotech Morning en 2026-09-29T14:16:27.291Z Novartis Bet $12 Billion on a Platform. Then the Data Came In. https://biotechmorning.com/news/roche-obesity-antibody-emugrobart-discontinued Biotech Morning en 2026-09-29T14:15:41.675Z Roche's Muscle Plan for Obesity Just Hit a Wall https://biotechmorning.com/news/telix-itm-radiopharmaceutical-acquisition Biotech Morning en 2026-09-29T14:14:56.464Z Telix Just Bet $2.35 Billion That Radioactive Drugs Are the Future https://biotechmorning.com/news/merck-discontinues-recarbrio-antibiotic-superbug-crisis Biotech Morning en 2026-09-29T14:14:13.725Z The Antibiotic That Hospitals Need but Merck Won't Make Anymore https://biotechmorning.com/news/genetics-heart-drugs-pelacarsen-ziltivekimab-fail Biotech Morning en 2026-09-29T14:13:29.654Z Genetics Said These Heart Drugs Should Work. The Patients Disagreed. https://biotechmorning.com/news/novartis-remibrutinib-ms-trial-results Biotech Morning en 2026-09-29T14:12:42.735Z The MS Drug That Doesn't Kill Your Immune Cells (It Just Calms Them Down) https://biotechmorning.com/news/merck-scibrunch-kras-g12d-deal Biotech Morning en 2026-09-29T14:11:57.811Z Merck Just Paid $400M for a Drug That Doesn't Exist Yet https://biotechmorning.com/news/kodiak-sciences-daybreak-eye-drug-comeback Biotech Morning en 2026-09-29T14:11:09.284Z The Eye Drug That Went From Dead to Stock-Doubling Overnight